The U.S. Food and Drug Administration (FDA) has expanded approval for a personalized cellular therapy developed at the University of Pennsylvania's Abramson Cancer Center, this time for the treatment of adult patients with ...
May 1, 2018
0
128
Among predictions of a second fracking boom in the US, the first evidence that chemicals found in ground water near fracking sites can impair the immune system will be published in Toxicological Sciences on May 1. The study, ...
May 1, 2018
0
15
Adolescents and young adults with acute leukemia have a survival advantage if they receive treatment at a pediatric cancer center versus an adult center, according to a new study.
Apr 18, 2018
0
4
Based on a novel approach to drug discovery, researchers at Georgetown Lombardi Comprehensive Cancer Center say an agent approved to treat a type of leukemia might also help young people with a much rarer and aggressive form ...
Jan 30, 2018
0
6
Researchers at The University of Western Australia have invented a new, highly sensitive way of monitoring leukaemia cells in the blood. The research, published in the journal Methods, describes the new technique that can ...
Jan 24, 2018
0
10
A team of researchers in Italy and Austria has determined that a drug approved to treat chronic lymphocytic leukemia (CLL) may be less effective in a particular subset of patients. The study, which will be published January ...
Jan 4, 2018
0
6
New findings by scientists at the University of Southampton could help to predict how people with the most common form of leukaemia will respond to chemotherapy. The findings will help doctors decide which type of treatment ...
Dec 19, 2017
0
6
Updated data on the first 134 chronic lymphocytic leukemia patients treated with single-agent acalabrutinib shows that the drug was well-tolerated in the majority of patients treated and responses were durable over time, ...
Dec 13, 2017
0
3
Acalabrutinib is a second-generation Bruton's tyrosine kinase (BTK) inhibitor, a newer class of drugs shown to improve the survival of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Researchers ...
Dec 13, 2017
0
1
Initial findings from a multi-national open-label phase Ib study of inhibitory drug therapy for relapsed or refractory acute myeloid leukemia (AML) have demonstrated a complete response in up to 50 percent patients say researchers ...
Dec 11, 2017
0
0
